SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     




J Nucl Med. 2008; 49 (Supplement 1):382P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Tylski, P.
Right arrow Articles by Buvat, I.
PubMed
Right arrow Articles by Tylski, P.
Right arrow Articles by Buvat, I.

Instrumentation & Data Analysis: Data Analysis & Management

Data Analysis & Management Posters

Which parameter should be considered to characterize tumor changes in patient monitoring using FDG-PET?

P. Tylski1, M. Dusart2, H. Necib1, B. Vanderlinden2 and I. Buvat1

1 UMR 8165 CNRS, Orsay, France; 2 Institut Jules Bordet, Bruxelles, Belgium

1613

Objectives: In patient monitoring based on FDG PET, the best way to characterize changes in tumor uptake remains to be found. We compared the evolution of various parameters potentially relevant for patient monitoring.

Methods: Seventeen pairs of PET/CT tumor images (GE Discovery LS system) acquired 10 to 12 weeks apart over the course of chemotherapy in lung cancer patients were considered. Four delineation methods (expert delineation, 40% of maximum intensity threshold, a contrast-dependent threshold and a fitting method) gave 4 independent volume (V) and total lesion glycolysis (TLG) estimates. 6 independent SUV estimates were obtained using the maximum SUV, and the mean SUV in the 4 delineated regions and in a fixed-size region. Percent changes in tumor features ({delta}V, {delta}SUV and {delta}TLG) were compared to the clinician’s interpretation based on visual assessment and maximum SUV.

Results: Percent changes in tumor features highly varied depending on the estimation method. Considering the 17 image pairs, the average coefficients of variation due to different estimation methods were 35% for {delta}SUV, 80% for {delta}TLG and 138% for {delta}V. The clinician found 9 responding (RT), 2 stable (ST) and 6 progressive tumors (PT). {delta}SUV averaged over the 6 SUV estimation methods was always < 0 for RT and > 0 for ST and PT, except in one case. Averaged {delta}V was > 0 for PT and < 0 for ST. {delta}TLG alone could not differentiate between RT, PT and ST, suggesting that joint analysis of {delta}V and {delta}SUV gave more information than {delta}TLG analysis.

Conclusions: When characterizing tumor changes, {delta}SUV was the most reproducible parameter as a function of the estimation method. Unlike the analysis of {delta}TLG alone, the combined analysis of {delta}V and {delta}SUV led to a tumor classification similar to that obtained from the clinician interpretation.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Tylski, P.
Right arrow Articles by Buvat, I.
PubMed
Right arrow Articles by Tylski, P.
Right arrow Articles by Buvat, I.